Journal
HAEMATOLOGICA
Volume 92, Issue 8, Pages 1119-1122Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11262
Keywords
valproic acid; 13-cis retinoic acid; myelodysplastic syndromes
Categories
Funding
- Oulu University Hospital
- Foundation for Blood Research, Finland
Ask authors/readers for more resources
Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to toxicity. According to international working group criteria, three patients (16%) responded to treatment. No correlation between VPA serum level, histone acetylation or clinical response was observed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available